Amgen and Generate Biomedicines entered a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. As part of the research collaboration, Amgen will pay $50 million in upfront funding for the initial five programs with a potential transaction value of $1.9 billion plus future royalties, and the option to add up to five additional programs. For each program, Amgen will pay up to $370 million in...